🔥🐔 BizChicken 🐔🔥

Companies Similar to Renalytix Plc

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

CareDx, Inc

CareDx, Inc logo
Market Cap: High
Employees: Medium

Allo Sure Kidney, Allo Map Heart, Allo Sure Heart, Allo Sure Lung, Tru Sight HLA, Olerup SSP, QTYPE, Ottr, Allo Seq Tx, Allo Seq cf DNA, Allo Seq HCT

Care Dx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide, offering a range of products for kidney, heart, lung, and stem cell transplants.

Tags: DNA, HLA typing, diagnostic solutions, healthcare, heart, kidney, lung, transplant

Symbol: CDNA

Recent Price: $21.18

Industry: Medical - Diagnostics & Research

CEO: Mr. John Walter Hanna Jr.

Sector: Healthcare

Employees: 635

Address: 1 Tower Place, South San Francisco, CA 94080

Phone: 415 287 2300

Leadership

  • John W. Hanna, President and Chief Executive Officer
  • Stacey Follon, Head of Human Resources
  • Marica Grskovic, PhD, Chief Strategy Officer
  • Jing Huang, PhD, Chief Data and AI Officer
  • Abhishek Jain, Chief Financial Officer
  • Keith Kennedy, Chief Operating Officer
  • Jessica Meng, Chief Commercial Officer
  • Jeffrey A. Novack, General Counsel
  • Kashif Rathore, Head of Software Engineering
  • Robert N. Woodward, PhD, Chief Scientific Officer

Last updated: 2024-12-31

Kiromic BioPharma, Inc.

Kiromic BioPharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

ALEXIS-ISO-1, ALEXIS-PRO-1

Kiromic Bio Pharma, Inc. is an artificial intelligence-driven allogeneic cell therapy company that develops multi-indication T cell therapies, leveraging the Gamma Delta T cell to target solid tumors. Key products include ALEXIS-ISO-1 and ALEXIS-PRO-1.

Tags: T cell therapies, artificial intelligence, biopharmaceutical, cell therapy, oncology

Symbol: KRBP

Recent Price: $0.93

Industry: Biotechnology

CEO: Mr. Pietro Bersani CPA, J.D.

Sector: Healthcare

Employees: 35

Address: 7707 Fannin, Houston, TX 77054

Phone: 832 968 4888

Leadership

  • Pietro Bersani, CPA, Director
  • Leonardo Mirandola, PhD, Chief Scientific Officer/Interim COO
  • Scott Dahlbeck, MD, PharmD, Chief of Staff
  • Brian Hungerford, Chief Financial Officer
  • Michael Nagel, Chairperson
  • Michael Catlin, Independent Director
  • Pam Misajon, Independent Director

Last updated: 2024-12-31

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: Highest

EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara, Inmazeb

Regeneron Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide, including treatments like EYLEA, Dupixent, Libtayo, and more.

Tags: biotechnology, diseases, healthcare, injections, medicines, pharmaceuticals, treatment

Symbol: REGN

Recent Price: $702.59

Industry: Biotechnology

CEO: Dr. Leonard S. Schleifer M.D., Ph.D.

Sector: Healthcare

Employees: 14165

Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707

Phone: 914 847 7000

Leadership

  • Leonard S. Schleifer, MD, PhD, Board co-Chair, President and Chief Executive Officer
  • George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer
  • Zoran Berkovic, Senior Vice President, Financial Planning and Analysis
  • Maya Bermingham, Senior Vice President, Public Policy and Government Affairs
  • Leonard Brooks, Senior Vice President, Treasurer
  • John Calabro, Senior Vice President, Internal Audit
  • Christina Chan, Senior Vice President, Corporate Affairs
  • Larry Coury, PhD, Senior Vice President, Associate General Counsel
  • Ryan Crowe, Senior Vice President, Investor Relations & Strategic Analysis
  • Matthew Everett, Senior Vice President, Global Procurement
  • Chris Fenimore, Senior Vice President, Finance and Chief Financial Officer
  • Rick Hall, Senior Vice President, Human Resources
  • Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit
  • Nouhad Husseini, Senior Vice President, Business Development
  • Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary
  • Melissa Lozner, Senior Vice President, Chief Compliance Officer
  • Marion McCourt, Executive Vice President, Commercial
  • Bob McCowan, Senior Vice President, IT and Chief Information Officer
  • Gonzalo Merino, PhD, Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel
  • Richard O’Neal, Senior Vice President, Market Access
  • Sally A. Paull, Executive Vice President, Human Resources
  • Smita Pillai, Senior Vice President, Culture and DEI and Chief DEI Officer
  • George Poth, Senior Vice President, Real Estate & Facilities Management
  • Alessandra Ravetti, Senior Vice President, Associate General Counsel
  • Kerry Reinertsen, PhD, Senior Vice President, Strategic Alliances
  • David Snow, Senior Vice President, Global Head, Dupixent Franchise
  • Mark Volpe, Senior Vice President, Tax
  • Bola Akinlade, MD, FACP, Senior Vice President, Clinical Development, Immunology and Inflammation
  • Hanne Bak, PhD, Senior Vice President, Preclinical Manufacturing and Process Development
  • Aris Baras, MD, Senior Vice President, Regeneron Genetics Center®
  • Ned Braunstein, MD, Executive Vice President, Regulatory Affairs and Global Patient Safety
  • Gang Chen, PhD, Senior Vice President, Protein Expression Sciences
  • Thomas DiCioccio, PhD, Senior Vice President, Pharmacometrics
  • Benjamin Drosman, Senior Vice President, Global Development Quality & Regulatory Compliance
  • Gregory Geba, MD, PhD, Senior Vice President, Global Development Scientific Council
  • Philip Gregory, DPhil, Senior Vice President, Regeneron Cell Medicines
  • Gary Herman, MD, Senior Vice President, Early Clinical Development and Experimental Sciences
  • Boaz Hirshberg, MD, Senior Vice President, Clinical Sciences General Medicine
  • Diana Hughes, MBBS, Senior Vice President, Global Patient Safety
  • Bari Kowal, Senior Vice President, Development Operations and Portfolio Management
  • Christos Kyratsous, PhD, Senior Vice President, Research
  • Johnathan Lancaster, MD, PhD, Senior Vice President, Global Medical Affairs
  • John Lin, MD, PhD, Senior Vice President, Immuno-Oncology and Head of Bispecifics
  • Israel Lowy, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Oncology
  • Lynn Macdonald, PhD, Senior Vice President, Research
  • Lori Morton, PhD, Senior Vice President, Research
  • Andrew Murphy, PhD, Executive Vice President, Research
  • Muriel O'Byrne, PhD, Senior Vice President, International Regulatory Affairs & Head, European Business Office
  • William Olson, PhD, Senior Vice President, Therapeutic Proteins
  • Mohammed Shameem, PhD, Senior Vice President, Formulations Development
  • L. Andres Sirulnik, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Hematology
  • Randy Soltys, PhD, Senior Vice President, Drug Safety and Pharmacometrics
  • Neil Stahl, PhD, Executive Vice President, Research and Development
  • Robert Vitti, MD, Senior Vice President, Clinical Trial Excellence Strategy
  • Brian Zambrowicz, PhD, Executive Vice President, Functional Genomics and Chief VelociGene® Operations
  • Rajesh Ahuja, Senior Vice President, Fill/Finish and External Manufacturing
  • Frederick Austin, Senior Vice President, Quality Control, Raheen
  • Christine Childrose, Senior Vice President, Human Resources and HR Operations
  • David Crenshaw, Senior Vice President, Associate General Counsel
  • Tikiri Dissanayake, Senior Vice President, IOPS Technical Operations
  • Patrice Gilooly, Senior Vice President, Quality Assurance and Operations
  • Jennifer McNay, PhD, Senior Vice President, CMC Regulatory Sciences and Industrial Affairs
  • Niall O’Leary, Senior Vice President and Site Head, IOPS Raheen
  • Scott Oberman, Senior Vice President, Supply Chain Operations
  • David Simon, Senior Vice President, IOPS Finance and Business Operations
  • Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply
  • Benjamin Yocum, Senior Vice President, Manufacturing Operations
  • James Wolfe, Senior Vice President, Process Sciences and Drug Product Engineering
  • Bonnie L. Bassler, PhD, Director
  • Michael S. Brown, MD, Director
  • N. Anthony Coles, MD, Chair of the Board
  • Joseph L. Goldstein, MD, Director
  • Kathryn Guarini, PhD, Director
  • Christine A. Poon, Lead Independent Director
  • Arthur F. Ryan, Director
  • Huda Y. Zoghbi, MD, Director
  • Samantha Dickon, Director, Development Program Management
  • Gervasio Batista, Sr. Scientist, Neuroscience
  • James K. Gibson, Senior Regional Director, Immunology/Pulmonary
  • Beth Brause, Director, Field Reimbursement Management
  • Eric Prendergast, Director, Pricing Strategy
  • Ashley Neff, Manager, Digital Communications
  • Shari Loock, Associate Director, Sourcing
  • Jennifer Davidson Hamilton, VP and Head of Precision Medicine
  • Yi Zhang, Director, Health Economics & Outcomes Research
  • Wilson Caldwell III, Director, GCO Vendor & Relationship Management
  • David Stein, Director, Medical Operations
  • Regeneron, Corporate
  • Grant Anicete, Biotech Production Specialist I / IOPS Rensselaer
  • Mary McKenna, Lead Quality Control Analyst / IOPS Raheen
  • Ashley Lebby, Lead Senior Biotech Production Specialist / IOPS Rensselaer
  • Varenka Rodriguez Diblasi, Principal Scientist, Bioinformatics
  • Jessie Brown, Manager, Integrative Translational Genetics
  • Gisu Eom, Lead Cloud DevOps Engineer
  • Carmen Kenworthy, Scientist, Velocigene
  • Ralph Hazlewood, Sr. Manager, Research Program Management
  • Brandy Bennett, Sr. Director, R&D Strategy & Operations

Last updated: 2024-12-31

Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

REN001

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing therapies for patients with rare genetic mitochondrial diseases. Its primary product, REN001, is a selective peroxisome proliferator-activated receptor delta agonist currently in clinical trials.

Tags: Clinical Trials, Genetic Disorders, Mitochondrial Diseases, Pharmaceuticals, Therapeutics

Symbol: RPHM

Recent Price: $18.20

Industry: Biotechnology

CEO: Mr. Gregory J. Flesher

Sector: Healthcare

Employees: 8

Address: 18575 Jamboree Road, Irvine, CA 92612

Phone: 619 733 3852

Last updated: 2024-12-31

DaVita Inc.

DaVita Inc. logo
Market Cap: Highest
Employees: Highest

Kidney Dialysis Services

Da Vita Inc. provides comprehensive kidney dialysis services through outpatient centers, serving patients with chronic kidney failure. They offer a variety of services including home-based hemodialysis, laboratory tests, disease management, and integrated care arrangements.

Tags: Clinical Services, Healthcare, Integrated Care, Kidney Dialysis, Outpatient Care

Symbol: DVA

Recent Price: $149.79

Industry: Medical - Care Facilities

CEO: Mr. Javier J. Rodriguez

Sector: Healthcare

Employees: 70000

Address: 2000 16th Street, Denver, CO 80202

Phone: 720 631 2100

Last updated: 2024-12-31

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. logo
Market Cap: Lowest
Employees: Low

TNX-1500, TNX-2900, TNX-801, TNX-1840, TNX-1850, TNX-3500

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company that focuses on developing therapies for immunology, rare diseases, infectious diseases, and central nervous system disorders. Key products include TNX-1500 for organ transplant and autoimmune diseases, TNX-2900 for Prader-Willi syndrome, and TNX-801 for smallpox prevention.

Tags: CNS, autoimmunity, biopharmaceutical, cancer, immunology, infectious disease, rare disease, therapeutics

Symbol: TNXP

Recent Price: $0.36

Industry: Biotechnology

CEO: Dr. Seth Lederman M.D.

Sector: Healthcare

Employees: 103

Address: 26 Main Street, Chatham, NJ 07928

Phone: 862 799 8599

Last updated: 2024-12-31

Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

Vadadustat

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for kidney disease patients, with a lead product vadadustat for treating anemia due to chronic kidney disease.

Tags: CKD, anemia, biopharmaceutical, chronic kidney disease, kidney diseases, therapeutics, vadadustat

Symbol: AKBA

Recent Price: $1.85

Industry: Biotechnology

CEO: Mr. John P. Butler MBA

Sector: Healthcare

Employees: 167

Address: 245 First Street, Cambridge, MA 02142

Phone: 617 871 2098

Last updated: 2024-12-31

Ardelyx, Inc.

Ardelyx, Inc. logo
Market Cap: High
Employees: Low

tenapanor

Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for gastrointestinal and cardiorenal therapeutic areas, including treatments for irritable bowel syndrome with constipation and hyperphosphatemia.

Tags: CKD, biopharmaceutical, cardiorenal, gastrointestinal, hyperkalemia, hyperphosphatemia, metabolic acidosis, tenapanor

Symbol: ARDX

Recent Price: $5.25

Industry: Biotechnology

CEO: Mr. Michael G. Raab

Sector: Healthcare

Employees: 267

Address: 400 Fifth Avenue, Waltham, MA 02451

Phone: 510 745 1700

Leadership

  • Justin Renz, Chief Financial & Operations Officer
  • Eric Foster, Chief Commercial Officer
  • Elizabeth Grammer, Esq., Chief Legal & Administrative Officer
  • Laura Williams, MD MPH, Chief Medical Officer
  • Robert Blanks, MS RAC, Chief Regulatory Affairs & Quality Assurance Officer
  • David Rosenbaum, PhD, Chief Development Officer
  • Mike Kelliher, Executive Vice President, Corporate Development and Strategy
  • Charon Spencer, Chief Human Resources Officer
  • David Mott, Chairman
  • Robert Bazemore, Director
  • William A. Bertrand, Jr., JD, Director
  • Muna Bhanji, R.Ph, Director
  • Onaiza Cadoret-Manier, Director
  • Mike Raab, Director
  • Richard Rodgers, Director

Last updated: 2024-12-31

Biodesix, Inc.

Biodesix, Inc. logo
Market Cap: Low
Employees: Low

Nodify Lung Nodule Risk Assessment

Biodesix, Inc. is a diagnostic solutions company offering blood-based lung tests and other diagnostic services to assess lung cancer risk and guide treatment pathways.

Tags: Bio-Rad partnership, COVID-19 testing, Gene Strat, blood-based tests, diagnostic solutions, lung cancer

Symbol: BDSX

Recent Price: $1.46

Industry: Medical - Diagnostics & Research

CEO: Mr. Scott Hutton

Sector: Healthcare

Employees: 217

Address: 2970 Wilderness Place, Boulder, CO 80301

Phone: 303 417 0500

Last updated: 2024-12-31

Nephros, Inc.

Nephros, Inc. logo
Market Cap: Lowest
Employees: Lowest

Water Solutions

Nephros, Inc. develops and sells high performance water solutions to medical and commercial markets, offering products for water filtration, pathogen detection, and renal health.

Tags: Medical Devices, Pathogen Detection, Renal Products, Ultrafiltration, Water Filtration

Symbol: NEPH

Recent Price: $1.48

Industry: Medical - Instruments & Supplies

CEO: Mr. Robert Banks

Sector: Healthcare

Employees: 31

Address: 380 Lackawanna Place, South Orange, NJ 07079

Phone: 201 343 5202

Leadership

  • Robert Banks, President & Chief Executive Officer
  • Judy Krandel, Chief Financial Officer
  • Michael Milman, VP, R&D & Manufacturing
  • Vashone Thomas, VP, Quality, Regulatory, & Human Resources
  • Judy Mazzini, Controller
  • Brianne McGuire, Director, Brand, Marketing, & Business Development
  • Devorah Serkin, Senior Director, Revenue Operations
  • Alfred Vargas, Director, Operations
  • Beth Johnson, Director, Research & Development

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

Renalytix Plc

Renalytix Plc logo
Market Cap: Lowest
Employees: Low

Kidney Intel X

Renalytix Plc develops AI-enabled diagnostic solutions for kidney diseases, using a platform that integrates blood biomarkers, genetics, and patient data to generate risk scores and support kidney disease management and drug development.

Tags: Artificial Intelligence, Biomarkers, Genetics, Healthcare, In Vitro Diagnostics, Kidney Diseases

Symbol: RNLX

Recent Price: $0.21

Industry: Medical - Healthcare Information Services

CEO: Mr. James R. McCullough M.B.A.

Sector: Healthcare

Employees: 102

Address: 1460 Broadway, New York, NY 10036

Phone: 646 397 3970

Last updated: 2024-12-31

Rezolute, Inc.

Rezolute, Inc. logo
Market Cap: Low
Employees: Lowest

RZ358

Rezolute, Inc. is a clinical stage biopharmaceutical company focused on developing transformative therapies for metabolic diseases related to chronic glucose imbalance. Its lead product, RZ358, is aimed at treating congenital hyperinsulinism.

Tags: biopharmaceutical, clinical stage, congenital hyperinsulinism, genetic disorder, glucose imbalance, metabolic diseases

Symbol: RZLT

Recent Price: $4.89

Industry: Biotechnology

CEO: Mr. Nevan Charles Elam J.D.

Sector: Healthcare

Employees: 59

Address: 201 Redwood Shores Parkway, Redwood City, CA 94065

Phone: 650 206 4507

Last updated: 2024-12-31

Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

XTX101

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients with a focus on tumor-selective therapies.

Tags: biotechnology, cancer treatment, checkpoint inhibitors, clinical-stage, immunotherapies

Symbol: XLO

Recent Price: $0.97

Industry: Biotechnology

CEO: Dr. Rene Russo BCPS, Pharm.D.

Sector: Healthcare

Employees: 73

Address: 828 Winter Street, Waltham, MA 02451

Phone: 617 430 4680

Last updated: 2024-12-31

Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Renazorb, UNI 494

Unicycive Therapeutics is a biotech company developing novel therapies for kidney diseases in the United States, focusing on treatments for hyperphosphatemia and acute kidney injury.

Tags: Renazorb, UNI 494, acute kidney injury, biotechnology, hyperphosphatemia, kidney diseases

Symbol: UNCY

Recent Price: $0.58

Industry: Biotechnology

CEO: Dr. Shalabh K. Gupta M.D., MPA

Sector: Healthcare

Employees: 14

Address: 4300 El Camino Real, Los Altos, CA 94022

Phone: 650 351 4495

Last updated: 2024-11-08

DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. logo
Market Cap: Low
Employees: Lowest

DM199

Dia Medica Therapeutics Inc. is a clinical stage biopharmaceutical company developing treatments for neurological and kidney diseases, including their lead drug candidate DM199 for chronic kidney disease and acute ischemic stroke.

Tags: acute ischemic stroke, biopharmaceutical, chronic kidney disease, clinical trials, kidney diseases, neurological diseases

Symbol: DMAC

Recent Price: $5.34

Industry: Biotechnology

CEO: Mr. Dietrich John Pauls MBA

Sector: Healthcare

Employees: 18

Address: Two Carlson Parkway, Minneapolis, MN 55447

Phone: 763 612 6755

Leadership

  • Rick Pauls, President & CEO
  • Lorianne Masuoka, Chief Medical Officer
  • Scott Kellen, Chief Financial Officer
  • Ambarish Shah, Ph.D., Chief Technology Officer
  • Dominic Cundari, Chief Commercial Officer
  • David Wambeke, Chief Business Officer
  • Rebekah de Vitry Fries, Vice President of Clinical Operations
  • Dr. Paolo Madeddu, MD, Senior Scientific Advisor and KLK1 Expert

Last updated: 2024-12-31

Immix Biopharma, Inc.

Immix Biopharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

IMX-110, IMX-111, IMX-120

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing tissue-specific therapeutics for oncology and inflammation, with clinical trials across the United States and Australia.

Tags: Biopharmaceuticals, Clinical Trials, Inflammation, Oncology, Tissue-Specific Therapeutics

Symbol: IMMX

Recent Price: $2.36

Industry: Biotechnology

CEO: Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.

Sector: Healthcare

Employees: 14

Address: 11400 West Olympic Boulevard, Los Angeles, CA 90064

Phone: 310 651 8041

Last updated: 2024-12-31

ProKidney Corp.

ProKidney Corp. logo
Market Cap: Medium
Employees: Low

Renal Autologous Cell Therapy

Pro Kidney Corp. is a clinical-stage biotechnology company focused on developing cellular therapy candidates, including Renal Autologous Cell Therapy, for the treatment of diabetic kidney disease and congenital anomalies of the kidney and urinary tract.

Tags: Phase III development, biotechnology, cellular therapy, clinical trials, diabetic kidney disease

Symbol: PROK

Recent Price: $1.75

Industry: Biotechnology

CEO: Dr. Bruce Culleton M.D.

Sector: Healthcare

Employees: 163

Address: 2000 Frontis Plaza Blvd., Winston-Salem, NC 27103

Phone: 336 999 7028

Leadership

  • Bruce Culleton, MD, Chief Executive Officer
  • James Coulston, CPA, Chief Financial Officer
  • Todd C. Girolamo, JD, MBA, Chief Legal Officer and Secretary
  • Nikhil Pereira-Kamath, Chief Business Officer
  • Darin J. Weber, PhD, Chief Regulatory Officer
  • Carla Poulson, Chief People Officer
  • Ulrich Ernst, PhD, EVP, Technical Operations
  • Emily Butler, PhD, SVP, Biometrics
  • Joseph Stavas, MD, MPH, SVP, Interventional Procedures and Patient Safety
  • Lucio Tozzi, SVP, Global Clinical Operations
  • Richard Williams, SVP, Information Technology

Last updated: 2024-12-31

Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

STK-001, STK-002

Stoke Therapeutics, Inc. is an early-stage biopharmaceutical company focused on developing antisense oligonucleotide medicines to treat genetic diseases. Their lead product, STK-001, is aimed at treating Dravet syndrome, while STK-002 targets autosomal dominant optic atrophy.

Tags: Dravet syndrome, antisense oligonucleotides, biopharmaceutical, epilepsy, genetic diseases, genetic medicine

Symbol: STOK

Recent Price: $10.80

Industry: Biotechnology

CEO: Dr. Edward M. Kaye M.D., Ph.D.

Sector: Healthcare

Employees: 110

Address: 45 Wiggins Avenue, Bedford, MA 01730

Phone: 781 430 8200

Leadership

  • Edward M. Kaye, M.D., Chief Executive Officer & Director
  • Jonathan Allan, J.D., General Counsel
  • Isabel Aznarez, Ph.D., Senior Vice President, Discovery Research and Co-Founder
  • Jason Hoitt, Chief Commercial Officer
  • Dawn Kalmar, Chief Communications Officer
  • Tommy Leggett, Chief Financial Officer
  • Shamim Ruff, Chief Regulatory Officer
  • Barry S. Ticho, M.D., Ph.D., FACC, Chief Medical Officer
  • Joan Wood, Chief Human Resources Officer
  • Adrian Krainer, Ph.D., Co-founder & Director
  • Arthur Tzianabos, Ph.D., Chairman
  • Jennifer Burstein, MBA, CPA, Director
  • Seth L. Harrison, M.D., Director
  • Arthur Levin, Ph.D., Director
  • Garry E. Menzel, Ph.D., MBA, Director
  • Ian F. Smith, Director
  • Julie Anne Smith, Director

Last updated: 2024-12-31

Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc. logo
Market Cap: Low
Employees: Low

VTX958

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule product candidates for the treatment of inflammatory diseases and autoimmune disorders. Key products include VTX958 for immune-mediated diseases, VTX002 for ulcerative colitis, and VTX2735 for systemic inflammatory diseases.

Tags: VTX002, VTX2735, VTX958, autoimmune disorders, biopharmaceutical, clinical trials, inflammatory diseases, small molecule

Symbol: VTYX

Recent Price: $2.23

Industry: Biotechnology

CEO: Dr. Raju S. Mohan Ph.D.

Sector: Healthcare

Employees: 73

Address: 662 Encinitas Boulevard, Encinitas, CA 92024

Phone: 760 593 4832

Last updated: 2024-12-31